Fig. 2

Upregulation of CD200 in the DG alleviates the depressive-like behaviors of mice induced by CSDS. A Experimental timelines for CSDS procedure, CD200Fc administration and behavioral testing. B Social interaction ratio in the SIT of control and CSDS mice with exogenous CD200Fc injection (n = 9–12 per group, two-way ANOVA with Fisher’s LSD test). C, D Immobility time in the TST (C) and FST (D) of control and CSDS mice with exogenous CD200Fc injection (TST, n = 10–12 per group; FST, n = 7–8 per group, two-way ANOVA with Fisher’s LSD test). E Total distance in the OFT of control and CSDS mice with exogenous CD200Fc injection (n = 11 for each group, two-way ANOVA with Fisher’s LSD test). F Experimental timelines for CSDS procedure, AAV–CD200 stereotaxical injection and behavioral testing. G Representative image showing the expression of AAV–CD200 in DG 4 weeks after virus vector injection. Scale bar: 300 μm. H Analysis of CD200 mRNA levels in DG after injection with AAV–CD200 virus. (n = 6 per group, Student’s t test). I Social interaction ratio in the SIT of control and CSDS mice with AAV–CD200 infusion (n = 8–9 per group, two-way ANOVA with Fisher’s LSD test). J, K Immobility time in the TST (J) and FST (K) of control and CSDS mice with AAV-CD200 infusion (TST, n = 9 for each group; FST, n = 9–11 per group, two-way ANOVA with Fisher’s LSD test). L Total distance in the OFT of control and CSDS mice with AAV-CD200 infusion (n = 9–11 per group, two-way ANOVA with Fisher’s LSD test). Data are expressed as mean ± SEM. *P < 0.05; **P < 0.01; ***P < 0.001. Ctrl, control. See Additional file 1: Table S2 for detailed statistical information